Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nanion Introduces New Product Family

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
CardioExcyte 96 for cardiac toxicity profiling and screening.

The CardioExcyte 96 is a non-invasive, high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements.

The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters.

Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very costly.

In-vivo methods give highly relevant information but are extremely low throughput allowing the analysis of only a handful of compounds.

In-vitro methods, such as automated patch clamp and other methods, offers higher throughput, however from one type of cardiac ion channels, typically over-expressed in cell lines.

Nanion’s new device, the CardioExcyte 96, has the potential to bridge this gap, by allowing reliable label-free measurements of short- and long-term compound effects on the beating pattern of stem cell-derived cardiomyocytes.

The system offers the highest impedance time-resolution (sub-millisecond) on the market and records from 96 wells in parallel.

Efficiency and ease-of-use are facilitated by an outstanding software package for data handling and export; thus an essential part of the CardioExcyte system.

Dr. Sonja Stölzle-Feix, Senior Scientist, Nanion Technologies, Munich, says: “CardioExcyte 96 is an easy-to-use system, providing impedance-based cardiac safety data from a diversity of stem cell-derived cardiomyocytes. Concentration- and time-dependence of a compound’s potential cardiotoxicity can efficiently be obtained. Further on, the powerful software, used for recordings and analysis, employs comprehensive beat investigation algorithms, displaying detailed beating kinetics in real-time. Data handling and export is straightforward, easy to grasp and yet very, very powerful.”

Dr. Niels Fertig, CEO of Nanion, continues: “CardioExcyte is a new branch in Nanion’s product portfolio. This label-free impedance system constitutes an excellent complement to automated patch clamp-based safety screening. It offers cost-efficient and highly relevant data on a drug candidate’s effect on intact networks of beating heart cells. Alteration of beating patterns can give a hint on what cardiac ion channel is affected, which is where detailed electrophysiology investigations take on the further investigations. Cardiac network responses offer a comprehensive view of a compound’s safety profile, without having to use in-vivo methods, and thus save time, costs and suffering.”

The CardioExcyte 96 is an automated device, recording from 96 wells at a time. With embedded electronics and a sophisticated sensor technology inside the well-plate based consumables, CardioExcyte 96 is a turn-key system for efficient impedance measurements, also allowing recordings residing inside of the incubator.

The system has been validated with stem cell derived cardiomyocytes from several providers (Axiogenesis, Cellular Dynamics International, GE Healthcare), as well as beating, 3D-clusters (Cellectis).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanion Opens US-office in New Jersey
Nanion expands its presence in the American market by the opening of its new headquarters to continue giving customer service.
Wednesday, February 18, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!